Probable drugs being tested on covid-19 by different countries from past few months
Abstract
Coronavirus disease is an infectious disease. At this time there is no specific vaccine or treatment for COVID-19. However, there are many ongoing trials evaluating potential treatment. As it spreads over 200 countries and territories across the globe, and was characterised as a pandemic by the world health organisation. Morethan 200 clinical trials of covid-19 treatment or vaccines that are either ongoing or recruiting patients. There are some drugs like Favipiravir, Hydroxychloroquine, Remdesivir, Losartan, etc which are mentioned in this article. Still some drugs have been under testing.
Downloads
References
https://www.livescience.com/coronavirus-covid-19-treatments.html
2. Japanese flu drug 'clearly effective' in treating coronavirus, says China
https://www.theguardian.com/world/2020/mar/18/japanese-flu-drug-clearly-effective-in-treating-coronavirus-says-china
3. Favipiravir
https://en.wikipedia.org/wiki/Favipiravir
4. https://www.nbcnews.com/health/health-news/fda-cautions-against-hydroxychloroquine-outside-hospital-setting-n1191266
5. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
https://www.ncbi.nlm.nih.gov/pubmed/32205204
6. Hydroxychloroquine for Potential Covid-19 Treatment
https://www.clinicaltrialsarena.com/projects/hydroxychloroquine/
7. Vitamin C and COVID-19
https://www.healthline.com/nutrition/vitamin-c-coronavirus#vitamin-c-covid-19
8. Vitamin C Can Shorten the Length of Stay in the ICU: A Meta-Analysis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521194/
9. A blood pressure drug
https://www.livescience.com/coronavirus-covid-19-treatments.html
10. What evidence suggests remdesivir could treat COVID-19?
https://www.biopharmadive.com/news/coronavirus-remdesivir-gilead-antiviral-drug-covid-19/573261/

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
2402abhinav@gmail.com


.